MA56121A - Procédés d'identification d'attributs de protéines thérapeutiques - Google Patents

Procédés d'identification d'attributs de protéines thérapeutiques

Info

Publication number
MA56121A
MA56121A MA056121A MA56121A MA56121A MA 56121 A MA56121 A MA 56121A MA 056121 A MA056121 A MA 056121A MA 56121 A MA56121 A MA 56121A MA 56121 A MA56121 A MA 56121A
Authority
MA
Morocco
Prior art keywords
methods
therapeutic protein
identifying therapeutic
protein attributes
attributes
Prior art date
Application number
MA056121A
Other languages
English (en)
Inventor
Pavel Bondarenko
Jill A Crouse-Zeineddini
Scott Thomas Kuhns
Andrew Nichols
Rachel Liuqing Shi
Gang Xiao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA56121A publication Critical patent/MA56121A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • G01N33/547—Synthetic resin with antigen or antibody attached to the carrier via a bridging agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA056121A 2019-06-05 2020-06-05 Procédés d'identification d'attributs de protéines thérapeutiques MA56121A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857637P 2019-06-05 2019-06-05
US202062968682P 2020-01-31 2020-01-31

Publications (1)

Publication Number Publication Date
MA56121A true MA56121A (fr) 2022-04-13

Family

ID=71944196

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056121A MA56121A (fr) 2019-06-05 2020-06-05 Procédés d'identification d'attributs de protéines thérapeutiques

Country Status (9)

Country Link
US (1) US20220260584A1 (fr)
EP (2) EP3980786B1 (fr)
JP (1) JP7636352B2 (fr)
AU (1) AU2020288652A1 (fr)
CA (1) CA3138941A1 (fr)
ES (1) ES2997211T3 (fr)
MA (1) MA56121A (fr)
MX (1) MX2021014733A (fr)
WO (1) WO2020247790A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230018939A1 (en) * 2019-11-26 2023-01-19 Merck Sharp & Dohme Llc On-line ultra performance hydrophobic interaction chromatography for monitoring at least one product attribute
EP4295158A1 (fr) * 2021-02-19 2023-12-27 Waters Technologies Corporation Procédés de cartographie peptidique de protéines du virus adéno-as associé (vaa)
KR20240000537A (ko) 2021-04-23 2024-01-02 암젠 인크 항-tslp 항체 조성물 및 이의 용도
EP4326762A2 (fr) 2021-04-23 2024-02-28 Amgen Inc. Anticorps anti-tslp modifiés
JP2024525715A (ja) * 2021-07-13 2024-07-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 生物製剤の生成物関連バリアントを決定するための質量分析法ベースの戦略
CA3227990A1 (fr) 2021-08-06 2023-02-09 Amgen Inc. Isolement de proteine therapeutique
WO2025076303A1 (fr) * 2023-10-05 2025-04-10 Amgen Inc. Dosage de protéomique peptidique associé au complexe majeur d'histocompatibilité (cmh) (mapp) pour l'évaluation du risque d'immunogénicité d'attributs biothérapeutiques
WO2025155798A2 (fr) * 2024-01-18 2025-07-24 Amgen Inc. Procédés d'analyse de protéines thérapeutiques co-formulées
WO2026003765A1 (fr) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations d'anticorps anti-récepteur 1 de l'interleukine 1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL217752B1 (pl) 2001-08-23 2014-08-29 Genmab As Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne
JPWO2006004214A1 (ja) * 2004-07-02 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 リン酸化タンパク質のプロテオーム解析方法
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP5038407B2 (ja) * 2006-06-14 2012-10-03 ジョンズ ホプキンズ ユニバーシティー 疾患のバイオマーカーとしてのアルブミン結合性タンパク質／ペプチド複合体
AR067045A1 (es) 2007-06-20 2009-09-30 Irm Llc Metodos y composiciones para el tratamiento de enfermedades alergicas
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8478537B2 (en) * 2008-09-10 2013-07-02 Agilent Technologies, Inc. Methods and systems for clustering biological assay data
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN104136461B (zh) * 2011-09-22 2021-06-08 安姆根有限公司 Cd27l抗原结合蛋白

Also Published As

Publication number Publication date
ES2997211T3 (en) 2025-02-14
EP4517327A3 (fr) 2025-05-07
WO2020247790A1 (fr) 2020-12-10
JP2022535042A (ja) 2022-08-04
MX2021014733A (es) 2022-04-06
EP3980786A1 (fr) 2022-04-13
AU2020288652A1 (en) 2021-11-18
EP3980786B1 (fr) 2024-10-16
EP4517327A2 (fr) 2025-03-05
JP7636352B2 (ja) 2025-02-26
CA3138941A1 (fr) 2020-12-10
US20220260584A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
MA56121A (fr) Procédés d'identification d'attributs de protéines thérapeutiques
EP3701066A4 (fr) Procédés et systèmes d'identification de protéines
EP3891755A4 (fr) Système d'identification, d'extraction et de prédiction de concepts cliniques et procédés associés
EP3948492A4 (fr) Appareil de panneau d'affichage intelligent et procédés associés
MA53094A (fr) Protéine de liaison à l'antigène anti-steap1
EP3834159A4 (fr) Systèmes et procédés permettant d'identifier l'identité d'un produit
MA52963A (fr) Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
EP3824796A4 (fr) Système d'endoscope
EP3491017A4 (fr) Procédés d'identification d'anticorps bloquant les récepteurs lilrb
EP3355930A4 (fr) Procédés et réactifs pour l'analyse d'interfaces protéine-protéine
EP3488018A4 (fr) Procédés et compositions pour l'identification de protéines
EP3634992A4 (fr) Procédés et compositions pour l'identification d'épitopes
EP3487998A4 (fr) Compositions et procédés d'identification de cibles polypeptidiques de liaison à l'arn
EP3864161A4 (fr) Système d'édition de gènes régulé
EP4081939A4 (fr) Procédé d'identification de l'authenticité d'un d'objet
EP3958727A4 (fr) Procédés d'analyse spatiale de protéines et kits associés
EP3464610A4 (fr) Composition de protéine et procédés d'analyse du microbiote
IL284471A (en) Methods for identifying free thiols in proteins
EP3756532A4 (fr) Système d'endoscope
EP3779458A4 (fr) Système d'analyse automatisé
EP3870972A4 (fr) Apprentissage automatique permettant l'identification de protéines
EP3859338A4 (fr) Réactif de dosage de l'hémoglobine, kit de dosage et procédé de dosage
DE602004018249D1 (de) Verfahren zur Dearomatisierung von Molkeprotein
EP3626073C0 (fr) Système d'aquaculture
EP3881325A4 (fr) Procédés d'identification de variants génétiques